The Development of Novel Drug Delivery Systems for Improved Therapeutic Efficacy: A Retrospective Study
Authors/Creators
- 1. Assistant Professor, Department of Pharmacology, Patna Medical College, Patna
- 2. Assistant Professor, Department of Surgery, Nalanda Medical College and Hospital, Patna
- 3. Professor, Department of Pharmacology, Patna Medical College, Patna
Description
Background: Novel drug delivery systems have sparked interest in pursuing better therapeutic efficacy in pharmacology. This retrospective study compared the effectiveness of liposomal formulations, systems based on nanoparticles, and conventional distribution methods, which included 200 participants. Methods: Treatment outcomes, safety profiles, and treatment durations were evaluated by thoroughly examining electronic medical information. All three medication distribution methods were compared using statistical tools, including logistic regression and t-tests. We gained IRB approval and adhered to all ethical considerations. Results: The clinical response rate of liposomal formulations (85%) was noticeably more significant than that of nanoparticle-based systems (75%), as well as traditional administration methods (60%), with a p-value of less than 0.001. When comparing liposomal formulations to nanoparticle-based systems (1.2 ± 0.6 events per patient) and traditional Delivery (1.5 ± 0.7 events per patient), the number of adverse events was lower (0.8 ± 0.4 occurrences per patient) (p = 0.014). Liposomal formulations resulted in shorter treatment duration (10.5 ± 2.3 weeks) when compared to nanoparticle-based systems (12.2 ± 3.1 weeks) and traditional Delivery (14.8 ± 4.2 weeks) (p < 0.001). Conclusion: Liposomal formulations show promise as an improved method of drug delivery, with better therapeutic efficacy and fewer adverse effects. These findings support the need for additional research into prospective randomised controlled trials to confirm the effectiveness of sophisticated drug delivery systems before they are widely used in clinical practice.
Abstract (English)
Background: Novel drug delivery systems have sparked interest in pursuing better therapeutic efficacy in pharmacology. This retrospective study compared the effectiveness of liposomal formulations, systems based on nanoparticles, and conventional distribution methods, which included 200 participants. Methods: Treatment outcomes, safety profiles, and treatment durations were evaluated by thoroughly examining electronic medical information. All three medication distribution methods were compared using statistical tools, including logistic regression and t-tests. We gained IRB approval and adhered to all ethical considerations. Results: The clinical response rate of liposomal formulations (85%) was noticeably more significant than that of nanoparticle-based systems (75%), as well as traditional administration methods (60%), with a p-value of less than 0.001. When comparing liposomal formulations to nanoparticle-based systems (1.2 ± 0.6 events per patient) and traditional Delivery (1.5 ± 0.7 events per patient), the number of adverse events was lower (0.8 ± 0.4 occurrences per patient) (p = 0.014). Liposomal formulations resulted in shorter treatment duration (10.5 ± 2.3 weeks) when compared to nanoparticle-based systems (12.2 ± 3.1 weeks) and traditional Delivery (14.8 ± 4.2 weeks) (p < 0.001). Conclusion: Liposomal formulations show promise as an improved method of drug delivery, with better therapeutic efficacy and fewer adverse effects. These findings support the need for additional research into prospective randomised controlled trials to confirm the effectiveness of sophisticated drug delivery systems before they are widely used in clinical practice.
Files
IJPCR,Vol15,Issue12,Article113.pdf
Files
(455.4 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:4b4ad2d0acc0bf0d2aeb1b66bd16f27e
|
455.4 kB | Preview Download |
Additional details
Dates
- Accepted
-
2023-11-30
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/15/IJPCR,Vol15,Issue12,Article113.pdf
- Development Status
- Active
References
- 1. Advances in hybrid vesicular-based drug delivery systems: Improved biocompatibility, targeting, therapeutic efficacy and pharmacokinetics of anticancer drugs, Current Drug Metabolism, 2022; 23: 9. 2. K. Chandel and N. Bhingradiya, Therapeutic efficacy of herbal formulations through novel drug delivery systems, Advances in Medical Diagnosis, Treatment, and Care, 2021; 1–42. 3. Basu, Enhancing the therapeutic efficacy of flavonoids as anticancer drugs through novel Drug Delivery Systems, Advances in Medical Diagnosis, Treatment, and Care, 2021; 207– 229. 4. M. Tabarzad, F. Ghorbani-Bidkorbeh, and T. Hosseinabadi, "Improved silymarin characteristics for clinical applications by Novel Drug Delivery Systems," Novel Drug Delivery Systems for Phytoconstituents, 2019; 195–222. 5. T. Kanwal et al., "Development of positively charged amphiphile containing selfnanoemulsifying drug delivery system for improved therapeutic efficacy of metronidazole against helicobacter pylori," Journal of Drug Delivery Science and Technology, 2023; 86: 104676. 6. Setia et al., Advances in hybrid vesicular-based drug delivery systems: Improved biocompatibility, targeting, therapeutic efficacy and pharmacokinetics of anticancer drugs," Current Drug Metabolism, vol. 23, no. 9, pp. 757–780, 2022. 7. P. Retnakumari and R. J. Anto, "Application of nano-drug delivery systems in improving the therapeutic efficacy of bioactive natural products," Advanced Pharmaceutical and Herbal Nanoscience for Targeted Drug Delivery Systems Part I, 2022; 104–132. 8. N. Surti, A. Mahajan, and J. Amrutiya, "Colonic drug delivery systems as multiunit potential: Therapeutic strategies and opportunities," Novel Drug Delivery Technologies, 2019;151– 181. 9. F. S. Almadi and S. I. Mallah, STAR particles in context: A novel contender in the search for optimized drug-delivery systems, Therapeutic Delivery, 2021; 12(3):175–181. 10. E. Chappel, Implantable drug delivery devices, Drug Delivery Devices and Therapeutic Systems, 2021; 129–156. 11. M. Patel, R. Shah, and K. Sawant, Recent advances in drug delivery strategies for improved therapeutic efficacy of Efavirenz, Recent Patents on Nanotechnology, 2020; 14(2): 119–127. 12. W. Men et al., Layer-by-layer ph-sensitive nanoparticles for drug delivery and controlled release with improved therapeutic efficacy in& nbsp; vivo, Drug Delivery, 2020; 27(1): 180– 190. 13. D. Wu, Review of: The effect of Spacers in dual drug-polymer conjugates toward combination therapeutic efficacy, 2021. 14. P. Paci and J. Loscalzo, Comprehensive network medicine-based drug repositioning via integration of therapeutic efficacy and side effects, 2023. 15. Multiple drug interaction, Reactions Weekly, 2022; 1918(1): 312–312.